/
BCPC
$169.21-$2.01 (-1.17%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$5.5B
32M shares
52-week range
$139.17 – $183.90
67% from low
Sector
CHEMICALS & ALLIED PRODUCTS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$36.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $643.7M | $643.7M | $703.6M | $799.0M | $942.4M | $922.4M | $953.7M | $1.04B |
| Cost of revenue | $439.4M | $432.3M | $479.7M | $555.8M | $661.9M | $620.4M | $617.5M | $666.5M |
| Gross profit | $204.3M | $211.4M | $223.9M | $243.2M | $280.5M | $302.1M | $336.2M | $370.6M |
| Gross margin | 31.7% | 32.8% | 31.8% | 30.4% | 29.8% | 32.7% | 35.3% | 35.7% |
| R&D | $11.6M | $11.4M | $10.3M | $13.5M | $12.2M | $15.0M | $16.8M | $18.5M |
| Operating income | $107.1M | $102.6M | $111.1M | $127.5M | $145.2M | $159.2M | $182.9M | $218.3M |
| EBITDA | $151.3M | $148.3M | $162.1M | $176.6M | $195.9M | $214.8M | $231.0M | $254.4M |
| Net income | $78.6M | $79.7M | $84.6M | $96.1M | $105.4M | $108.5M | $128.5M | $154.8M |
| Net margin | 12.2% | 12.4% | 12.0% | 12.0% | 11.2% | 11.8% | 13.5% | 14.9% |
| EPS (diluted) | 2.42 | 2.45 | 2.60 | 2.94 | 3.25 | 3.35 | 3.93 | 4.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.1B | $5.24 | $5.12–$5.41 | 2 |
| 2027 | $1.2B | $5.51 | $5.37–$5.65 | 2 |
| 2028 | $1.2B | $0.00 | $0.00–$0.00 | 1 |
| 2029 | $1.3B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$174.68
Price
$169.21
Implied upside
+3%
Peer comparison
Balchem Corporation
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
www.balchem.com- Employees
- 1,368
- IPO / List date
- Jun 3, 1986
- HQ
- MONTVALE, NJ
Held by traders on TradeandTell
No one on the platform currently holds BCPC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 177,000 | $30.0M |
| Bridgewater Associatesas of 2026-03-31 | 17,313 | $2.9M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.55% ($2.62/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-23 | $0.9600 | 2026-01-20 |
| 2024-12-26 | $0.8700 | 2025-01-17 |
| 2023-12-26 | $0.7900 | 2024-01-19 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2010-01-21 | 3-for-2 |
| 2007-01-22 | 3-for-2 |
Recent trades on TradeandTell
No one on the platform has traded BCPC yet.
